Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Other Non-Current Liabilities (2022 - 2026)

TriSalus Life Sciences has reported Other Non-Current Liabilities over the past 5 years, most recently at $9.1 million for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities rose 10.39% year-over-year to $9.1 million; the TTM value through Mar 2026 reached $9.1 million, up 10.39%, while the annual FY2025 figure was $10.1 million, 37.06% up from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $9.1 million at TriSalus Life Sciences, down from $10.1 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $18.6 million in Q4 2023 and troughed at $369000.0 in Q4 2022.
  • A 5-year average of $8.6 million and a median of $8.0 million in 2024 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 4949.32% in 2023 and later crashed 60.28% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $369000.0 in 2022, then skyrocketed by 4949.32% to $18.6 million in 2023, then crashed by 60.28% to $7.4 million in 2024, then skyrocketed by 37.06% to $10.1 million in 2025, then dropped by 10.54% to $9.1 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for TLSI at $9.1 million in Q1 2026, $10.1 million in Q4 2025, and $5.0 million in Q3 2025.